APIMEDS PHARMACEUTICALS US, INC. Increase (Decrease) in Prepaid Expense and Other Assets
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$22.62 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$296.01K, a 116.55% decline year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $273.39K.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $193.46K.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $431.01K.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.41M.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$1.99K, a 117.19% decline from fiscal 2023.
- APIMEDS PHARMACEUTICALS US, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $11.59K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$296.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$22.62K 10-Q · filed 2026-08-14 | $170.83K derived: sum of 3 quarters · filed 2026-08-14 | $601.85K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $273.39K 10-Q · filed 2026-05-26 | $466.85K derived: sum of 2 quarters · filed 2026-05-26 | $897.86K derived: sum of 3 quarters · filed 2026-05-26 | $2.69M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $193.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $624.47K derived: sum of 2 quarters · filed 2026-05-04 | $2.41M derived: sum of 3 quarters · filed 2026-08-14 | $2.41M 10-K · filed 2026-05-04 |
| 2025-09-30 | $431.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.22M derived: sum of 2 quarters · filed 2026-08-14 | $2.22M 10-Q · filed 2025-11-12 | $2.22M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.79M 10-Q · filed 2026-08-14 | $1.79M derived: sum of 3 quarters · filed 2026-08-14 | $1.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$40.00 10-Q · filed 2026-05-26 | -$774.00 derived: sum of 2 quarters · filed 2026-05-26 | -$774.00 derived: sum of 3 quarters · filed 2026-05-26 | -$775.00 derived: sum of 4 quarters · filed 2026-05-26 |
| 2024-12-31 | -$734.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | -$734.00 derived: sum of 2 quarters · filed 2026-05-04 | -$735.00 derived: sum of 3 quarters · filed 2026-05-04 | -$1.99K 10-K · filed 2026-05-04 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.00 derived: sum of 2 quarters · filed 2025-11-12 | -$1.26K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$1.26K 10-Q · filed 2025-08-19 | ||
| 2024-03-31 | -$1.26K 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | $11.59K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |